Table 1 Baseline Characteristics

From: Cytoreductive surgery and hyperthermic intrathoracic chemotherapy in thymic epithelial tumors with pleural spread or recurrence: a prospective, single-arm, phase II study

Variables

Total (N = 45)

Sex, No. (%)

 Male

22 (48.9)

 Female

23 (51.1)

Age, No. (%)

 ≤65 years old

38 (84.4)

 >65 years old

7 (15.6)

Charlson Comorbidity Index, No. (%)

 ≤3

38 (84.4)

 >3

7 (15.6)

Pre-treatment MG, No. (%)

 Yes

12 (26.7)

 No

33 (73.3)

MGFA grade

 I

6 (13.3)

 II

4 (8.9)

 III

1 (2.2)

 IV

1 (2.2)

Mode of pleural metastasis, No. (%)

 DNT

12 (26.7)

 TPR

33 (73.3)

Pathology, No. (%)

 A

1 (2.2)

 AB

1 (2.2)

 B1

3 (6.6)

 B2

14 (31.1)

 B2/B3 mix

10 (22.2)

 B3

10 (22.2)

 Thymic carcinoma

6 (13.3)

Pathological stage T, No. (%)

 T0

31 (68.9)

 T+

14 (31.1)

Pathological stage N, No. (%)

 N0

39 (86.7)

 N+

6 (13.3)

Pathological TNM stage, No. (%)#

 IVA

40 (88.9)

 IVB

5 (11.1)

Tumor location, No. (%)

 Left thorax

11 (24.4)

 Right thorax

34 (75.6)

  1. CCI Charlson comorbidity index, MG myasthenia gravis, MGFA Myasthenia Gravis Foundation of America, DNT de novo Masaoka stage IVA TETs, TPR TETs with pleural recurrence, pT+ postoperative pathological T stage positive, pN+ postoperative pathological N stage positive, TNM tumor-node-metastasis.
  2. # Thymic malignancies were graded by AJCC/UICC/IASLC/ITMIG TNM stage (9th edition).